stars 1 stars 2 stars 3

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

View Top Employees from Mesoblast Limited
Ticker MESO
Revenue $32 million
Funding $434.3 million
Employees 92 (92 on RocketReach)
Founded 2004
Address Level 38, 55 Collins St, Melbourne, Victoria 3000, AU
Phone +61 3 9639 6036
Fax +61 3 9639 6030
Industry Biotechnology, Biotechnology Research, Pharmaceuticals, Cell-based therapies, Healthcare, Science and Engineering, Drug Discovery, Cellular Medicines, Health Care, Mesenchymal Lineage Adult Stem Cells, Health Diagnostics, Regenerative Medicine
Web Rank 4 Million
Keywords Mesoblast, Mesbloast, Mesoblast Ltd., Pharmaceutical Companies New York, Mesoblast Intervertebral Disc
SIC SIC Code 873 Companies, SIC Code 87 Companies
NAICS NAICS Code 621 Companies, NAICS Code 62151 Companies, NAICS Code 6215 Companies, NAICS Code 32 Companies, NAICS Code 62 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies

Mesoblast Limited Questions

The Mesoblast Limited annual revenue was $32 million in 2024.

Normand Davidzon is the Vice President, Engineering Technology of Mesoblast Limited.

92 people are employed at Mesoblast Limited.

Mesoblast Limited is based in Melbourne, Victoria.

The NAICS codes for Mesoblast Limited are [621, 62151, 6215, 32, 62, 3254, 325].

The SIC codes for Mesoblast Limited are [873, 87].

Top Mesoblast Limited Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users